Lung cancer trial targets tumor diversity to outsmart resistance

NCT ID NCT02314481

Completed Knowledge-focused Sponsor: University College, London Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 trial studied 50 people with non-small cell lung cancer to see if differences within a tumor (called heterogeneity) affect how well treatments work. Patients received one of four drugs based on their tumor's genetic changes: atezolizumab (immunotherapy), vemurafenib, alectinib, or trastuzumab emtansine. The goal was to understand why some tumors resist treatment and to find better ways to match drugs to patients.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Atezolizumab, Vemurafenib, Alectinib, Trastuzumab emtansine
What this could lead to: If successful, this could help doctors choose the best treatment for lung cancer based on a tumor's genetic makeup, improving outcomes.
What could go wrong: This is a small, early-phase trial with no control group, so results may not apply to all patients. The drugs also have side effects like immune reactions or organ damage.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Genomic Instability non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NON-SMALL CELL LUNG CANCER

Contacts and locations

Locations

Univeristy College London Hospital

London, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.